Drug Trial Radar · NCT06008054
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
376
Planned (sponsor's estimate)
Start
Nov 16, 2023
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- First posted
- Aug 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II study is a clinical study to explore the efficacy and safety of SI-B003 Monotherapy, BL-B01D1+SI-B003 Combination Therapy and BL-B01D1+PD-1 Monoclonal Antibody in patients with locally advanced or metastatic esophageal cancer, gastric cancer, colorectal cancer and other gastrointestinal tumors.
Conditions
- Esophageal Cancer
- Gastric Cancer
- Colorectal Cancer
Interventions
SI-B003Drug
Administered by intravenous infusion every 3 weeks (Q3W).
BL-B01D1Drug
Administered by intravenous infusion for a cycle of 3 weeks.
PD-1 Monoclonal AntibodyDrug
Administration by intravenous infusion for a cycle of 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Up to approximately 24 months
- Recommended Phase II Dose (RP2D)Time frame: Up to approximately 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.